Clinical trials
Advanced Lung Cancer clinical trials
Below are recruiting advanced lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,300 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT06054854Recruiting
Lung Cancer Biomarker Study (BIRD Biobank)
This study collects blood, tissue, and other samples from people with lung nodules, suspected lung cancer, or confirmed lung cancer to find better ways to diagnose and treat the disease. By joining, you help researchers discover new biomarkers that could improve care for future patients.
ToulouseAges 18 years+ - NCT04980716RecruitingPhase 3
Heart-based early intervention for stage III lung cancer using heart signals
This trial tests an early heart-focused intervention guided by a special heart recording (impedance cardiography) in people with locally advanced, unresectable stage III non-small cell lung cancer. The goal is to improve heart-related safety during planned radiation and chemotherapy, with or without immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT05903833RecruitingPhase 2
Study pembrolizumab and lenvatinib for advanced vulvar cancer
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
AugsburgAges 18 years+ - NCT05752552RecruitingPhase 1
Safety study of a MET-targeting pill for advanced lung cancer
This Phase 1 trial tests DO-2 to see how safe it is and how the body absorbs it (pharmacokinetics) in people with advanced or metastatic lung cancer. It is for tumors that have a specific MET exon 14 “skipping” mutation and for whom standard treatments are no longer an option.
BrusselsAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Goodyear, ArizonaAges 18 years+ - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04611867Recruiting
Test “BetterEveryDay” patient-reported care for pancreatic or bile cancer
This study studies how a patient “reporting” program (called PRO) works for people with advanced pancreatic or bile-tract cancer. It may help teams understand symptoms and needs earlier to improve care and support during treatment.
HerlevAges 18 years+ - NCT06827236RecruitingPhase 1/Phase 2
Testing a new combination treatment for advanced breast cancer
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
Beverly Hills, CaliforniaAges 18 years+ - NCT06217185RecruitingPhase 4
Pyrotinib and trastuzumab with chemo for HER2+ advanced breast cancer
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
Shijiazhuang, HebeiAges 18–70 - NCT07704658RecruitingPhase 4
Pralsetinib drug interaction study for advanced solid tumors
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
Logroño, La RiojaAges 18 years+ - NCT07559097RecruitingPhase 1/Phase 2
Methotrexate-loaded vesicles injected into spine fluid for lung cancer spread to brain membranes
This study tests a new way to deliver a cancer drug directly into the fluid around your brain and spinal cord to treat lung cancer that has spread to the membranes covering the brain. It may help patients whose cancer hasn't responded to standard treatments.
Zhengzhou, HenanAges 18 years+ - NCT06422403RecruitingPhase 2
Study on giving immunotherapy less often for advanced cancer
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
SingaporeAges 21–99 - NCT07358806RecruitingPhase 1
Study of OCT-598 for advanced solid tumors
This trial tests a new drug called OCT-598, alone or with chemotherapy, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
Goyang-siAges 18 years+ - NCT07149649RecruitingPhase 2/Phase 3
Magnesium for advanced lung cancer
This trial tests if adding magnesium supplements to standard first-line treatment (chemotherapy plus immunotherapy) improves outcomes for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. It is for patients who have not had prior treatment for metastatic disease.
AarauAges 18 years+ - NCT07028489Recruiting
Studying a standard-care comparison group for advanced EGFR-mutant lung cancer
This trial collects information from people with a specific type of advanced lung cancer to create a comparison group. It helps researchers understand how well new treatments work without giving any experimental medicine.
Monterey, CaliforniaAges 18 years+ - NCT06865339RecruitingPhase 2
Radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
The Bronx, New YorkAges 18 years+ - NCT05442060RecruitingPhase 2
Test medicine add-on to erlotinib for EGFR lung cancer
This Phase 2 trial tests whether adding OBI-833/OBI-821 to the standard targeted pill erlotinib works better for some people with EGFR-mutated lung cancer. It may help shrink tumors that already started responding to erlotinib.
Taipei, Beitou DistrictAges 20 years+ - NCT06564324RecruitingPhase 3
Comparing taletrectinib to standard therapy for ROS1-positive lung cancer
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
Hefei, AnhuiAges 18 years+ - NCT06350097RecruitingPhase 3
Osimertinib with or without datopotamab deruxtecan for first-line EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
Fountain Valley, CaliforniaAges 18 years+ - NCT05351788RecruitingPhase 2
Study drug combo for advanced lung cancer with specific gene results
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
Guangzhou, GuangdongAges 18–75 - NCT05168566RecruitingPhase 2
Sutetinib for lung cancer with a specific EGFR change
This Phase 2 study tests sutetinib capsules in people with advanced (locally advanced or metastatic) non-small cell lung cancer. It’s for tumors that have a specific, uncommon EGFR mutation, and aims to see how well the drug can control the cancer with limited prior chemotherapy.
Glendale, CaliforniaAges 18 years+
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced lung cancer?
- Yes. Clin2 currently lists 1,300 recruiting advanced lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- EGFR Mutant Advanced Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.